Abstract
Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.
Original language | English |
---|---|
Pages (from-to) | 465-467 |
Number of pages | 3 |
Journal | Pediatric Blood and Cancer |
Volume | 54 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar 2010 |
Keywords
- Filgrastim
- Pegfilgrastim
- R-Hu-granulocyte-stimulating factor
- Severe congenital neutropenia
ASJC Scopus subject areas
- Hematology
- Oncology
- Pediatrics, Perinatology, and Child Health